Human Immunodeficiency Virus Rebound in Blood and Seminal Plasma Following Discontinuation of Antiretroviral Therapy

被引:0
|
作者
Costiniuk, Cecilia T. [1 ]
Kovacs, Colin [2 ,3 ]
Routy, Jean-Pierre [4 ,5 ]
Singer, Joel [6 ]
Gurunathan, Sanjay [7 ]
Sekaly, Rafick-Pierre [8 ]
Angel, Jonathan B. [1 ,9 ]
机构
[1] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Maple Leaf Med Clin, Toronto, ON, Canada
[4] McGill Univ, Div Hematol, Ctr Hlth, Montreal, PQ, Canada
[5] McGill Univ, Serv Immunol, Ctr Hlth, Montreal, PQ, Canada
[6] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada
[7] Sanofi Pasteur, Swiftwater, PA USA
[8] CHU Montreal, Ctr Rech, Montreal, PQ, Canada
[9] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada
基金
加拿大健康研究院;
关键词
SEXUAL TRANSMISSION; HIV-1; TRANSMISSION; SEMEN; INFECTION; INHIBITOR;
D O I
10.1089/aid.2011.0343
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although there is discordance between human immunodeficiency virus (HIV) blood plasma and seminal plasma viral loads (VL), little is known about the dynamics of VL rebound in these compartments upon discontinuation of highly active antiretroviral therapy (HAART). Therefore, we sought to examine the relationship between blood and semen VL rebound after discontinuation of HAART. Participants in this substudy were men enrolled from two centers of a multicenter, placebo-controlled randomized trial of HIV therapeutic vaccination using ALVAC with or without Remune. With at least 2 years of sustained virologic suppression and following a 20-week vaccination course, subjects underwent structured HAART interruption. Fourteen men provided semen samples. Seven to 12 weeks after HAART interruption, all 14 men had detectable blood VLs whereas 8 of 14 had detectable seminal VLs. There was a significant correlation between blood and seminal VLs (Spearman r=0.58, p=0.03) at the time of semen collection. An earlier time to detectable blood VL after HAART interruption was associated with higher seminal VL (Spearman r=-0.64, p=0.02). These findings support the compartmentalization of HIV and underscore the importance of understanding the genital tract as an HIV reservoir in the quest to minimize HIV transmission.
引用
下载
收藏
页码:266 / 269
页数:4
相关论文
共 50 条
  • [21] Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy
    Esposito, S
    Bojanin, J
    Porta, A
    Cesati, L
    Gualtieri, L
    Principi, N
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (12) : 1117 - 1120
  • [22] Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy
    Guex, AC
    Radziwill, AJ
    Bucher, HC
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (03) : 602 - 603
  • [23] Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Markowitz, M
    Jin, X
    Hurley, A
    Simon, V
    Ramratnam, B
    Louie, M
    Deschenes, GR
    Ramanathan, M
    Barsoum, S
    Vanderhoeven, J
    He, T
    Chung, C
    Murray, J
    Perelson, AS
    Zhang, LQ
    Ho, DD
    JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (05): : 634 - 643
  • [24] Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy
    McDermott, JL
    Giri, AA
    Martini, I
    Bono, M
    Giacomini, M
    Campelli, A
    Tagliaferro, L
    Cara, A
    Varnier, OE
    JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (07) : 2361 - 2365
  • [25] Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy
    Mullins, James I.
    Frenkel, Lisa M.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 215 : S119 - S127
  • [26] ANTIRETROVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - HOPE AND DESPAIR
    PICARD, O
    BIOMEDICINE & PHARMACOTHERAPY, 1994, 48 (02) : 85 - 88
  • [27] Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
    Singh, N
    Berman, SM
    Swindells, S
    Justis, JC
    Mohr, JA
    Squier, C
    Wagener, MM
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (04) : 824 - 830
  • [28] Antiretroviral therapy and the human immunodeficiency virus - improved survival but at what cost?
    Bradbury, R. A.
    Samaras, K.
    DIABETES OBESITY & METABOLISM, 2008, 10 (06): : 441 - 450
  • [29] ANTIRETROVIRAL THERAPY FOR INFECTION DUE TO HUMAN-IMMUNODEFICIENCY-VIRUS IN CHILDREN
    PIZZO, PA
    WILFERT, C
    PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1994, 5 (05): : 273 - 295
  • [30] NEUROMUSCULAR COMPLICATIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND ANTIRETROVIRAL THERAPY
    MILLER, RG
    WESTERN JOURNAL OF MEDICINE, 1994, 160 (05): : 447 - 452